By 2026, the clinical paradigm for ACE inhibitors has shifted toward their role in "life-course" management. This document explores how these medications prevent the progression of the two most common chronic conditions in aging populations: heart failure and chronic kidney disease.

1. Heart Failure with Reduced Ejection Fraction (HFrEF)

In patients with heart failure, the body often enters a "vicious cycle" where the heart weakens, causing the body to release hormones like Angiotensin II. While these hormones help in the short term by raising blood pressure, they eventually cause the heart muscle to become stiff and scarred—a process known as pathological remodeling.

ACE inhibitors break this cycle. Data from longitudinal studies reaching their conclusion in 2025 have shown that consistent use can increase life expectancy by several years in symptomatic patients. They do this by reducing the "afterload" (the resistance the heart pumps against) and directly inhibiting the cellular signals that tell the heart muscle to thicken or scar.